Daejin Kim

Daejin Kim

Auto-generated profile, based on publicly available information

Daejin Kim

Department of Internal Medicine, Daegu Fatima Hospital, Daegu, Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2021 in Gut and Liver
Verified
Journal Article
Open access
PDF file
YLYoonsuk Lee
Yoonsuk Lee
CCChang Min Cho
Chang Min Cho
KCKwang Bum Cho
Kwang Bum Cho
JHJun Heo
Jun Heo
MJMin Kyu Jung
Min Kyu Jung
HKHyunsoo Kim
Hyunsoo Kim
Yoon Suk Lee, Chang Min Cho, Kwang Bum Cho, Jun Heo, Min Kyu Jung, Sung Bum Kim, Kook Hyun Kim, Tae Nyeun Kim, Dong Wook Lee, Jimin Han, Ho Gak Kim, Daejin Kim, and Hyunsoo Kim. Gut and Liver 2021;15:459-65. https://doi.org/10.5009/gnl19304

31 March 2022 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
YLYujin Lee
Yujin Lee
JLJaekwang Lee
Jaekwang Lee
HKHyunsoo Kim
Hyunsoo Kim
CPChangkeun Park
Changkeun Park
JJJaekwon Jung
Jaekwon Jung
HRHanjun Ryu
Hanjun Ryu
Acute liver failure due to malignant melanoma is uncommon. We presents a case of acute liver failure secondary to hepatic infiltration of a malignant melanoma. An 86-year-old man was admitted with elevated liver enzymes and an increased lactate dehydrogenase level. His condition progressed to acute liver failure, but the etiology of liver failure was unclear. Esophagogastroduodenoscopy was performed to evaluate dyspepsia, which showed signs indicative of malignant melanoma. Based on the endoscopy findings and elevated liver enzyme levels, liver biopsy was performed to confirm the presence of malignant melanoma. Hepatic infiltration of malignant melanoma was observed histologically. However, massive and diffuse liver metastasis is very rare and difficult to identify on imaging studies. If the etiology of liver failure is unclear, diffuse metastatic melanoma infiltration should be considered as differential diagnosis. Early liver biopsy can help to clarify the diagnosis.

1 May 2008 in Journal of Physics and Chemistry of Solids
Verified
Journal Article
Closed access
DKDaejin Kim
Daejin Kim
DJDong Hyun Jung
Dong Hyun Jung
SCSang Beom Choi
Sang Beom Choi
JYJiHye Yoon
JiHye Yoon
JKJaheon Kim
Jaheon Kim
SCSeung-Hoon Choi
Seung-Hoon Choi

30 May 2021 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
SYSang Myung Yeo
Sang Myung Yeo
JLJae Kwang Lee
Jae Kwang Lee
HKHyun Soo Kim
Hyun Soo Kim
CPChang Geun Park
Chang Geun Park
JJJae Kwon Jung
Jae Kwon Jung
HRHan Jun Ryu
Han Jun Ryu
Angiolipoma is a benign fatty neoplasm that has components of proliferating blood vessels. These types of lesions commonly occur in the subcutaneous tissue of the limbs and trunk. Angiolipoma in the gastrointestinal tract is extremely rare, and the final diagnosis generally depends on histological examination of the excised biopsy. In most previously reported cases, the lesions were diagnosed and treated with surgical management. In this study, we report a case of gastric angiolipoma of approximately 4 cm in size that was diagnosed and treated with endoscopic submucosal dissection.

10 March 2021 in The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Verified
Journal Article
Open access
PDF file
JHJaehyun Ha
Jaehyun Ha
DKDaejin Kim
Daejin Kim
HKHyunsoo Kim
Hyunsoo Kim
CPChang Keun Park
Chang Keun Park
JJJaekwon Jung
Jaekwon Jung
HRHanjun Ryu
Hanjun Ryu
Traditionally, tissue biopsies of kidney lesions are usually performed with CT or percutaneous ultrasound guidance, but biopsies using EUS have rarely been reported. In this report, we describe a case of renal cell carcinoma (RCC) diagnosed using EUS-guided fine-needle aspiration biopsy. A 75-year-old woman taking aspirin due to stable angina continued to exhibit weight loss and anemia and visited the gastroenterology department. No bleeding was observed on upper and lower gastrointestinal endoscopy. A contrast-enhanced mass was observed in the left kidney, accompanied by 8.9×10.8 cm-sized necrosis suggesting RCC on abdominal CT. Chest CT showed masses in both lungs. We planned to administer targeted therapy after pathological confirmation using EUS. Aspirin was continued, and we performed fine-needle biopsy using a 22-gauge needle three times. No adverse events were observed after the procedure. Pathological examination confirmed RCC, clear cell type, and the patient is currently undergoing treatment with sunitinib. EUS-guided fine-needle aspiration biopsy is safe for liver, pancreatic, or other tumors accessible from the upper gastrointestinal tract. This technique shows fewer adverse events. To the best of our knowledge, there have been no other reports on EUS-guided fine-needle aspiration biopsy to identify RCC in Korea.

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
JLJong Suk Lee
Jong Suk Lee
SLSeon Myeong Lee
Seon Myeong Lee
JCJaehyuk Choi
Jaehyuk Choi
EPEunjin Park
Eunjin Park
JLJongsoo Lee
Jongsoo Lee
ICIn Young Choi
In Young Choi
Obesity is a major risk factor for a number of metabolic disorders such as hyperlipidemia, glucose intolerance, and T2DM. Recent researches indicated a stimulatory effect of glucagon (GCG) on energy expenditure and appetite inhibition, suggesting the utilization of GCG as a pharmacological therapy for obesity and related metabolic disorders. In line with this, we previously observed that chronic treatment of HM15136, a novel long-acting glucagon analog, conferred efficient body weight loss (BWL) in DIO mice. Here, we further investigated the potential benefits of HM15136 in obesity-related metabolic disorders. In DIO mice, time-course change in fat mass, liver triglyceride (TG), and fasting blood glucose (FBG) was determined. Chronic treatment of HM15136 was associated with progressive BWL (-37.5% vs. vehicle (Veh) at day17) and fat mass reduction with little effect on lean mass, confirming its potent anti-obesity effect. Interestingly, despite marginal BWL at initial drug treatment period, significant reduction in blood TG (-56.5% vs. Veh at day2) and subsequent liver TG (-41.5% vs. Veh at day7) was achieved, and maintained thereafter. Moreover, the TG lowering both in blood and liver was followed by sustainable FBG lowering, suggesting that rapid depletion of lipid, the main sources for gluconeogenesis, might contribute to FBG control by HM15136. To evaluate the potential effect on post-prandial glucose control, oral glucose tolerance test (oGTT) was performed, and reduced BG level during oGTT was observed as BWL occurred. Time-dependent reduction in HOMA-IR evidenced the insulin sensitivity improvement. To our knowledge, this is the first study demonstrating the potential benefits of chronic GCG engagement in the management of BW, blood lipid, and even BG. Based on these results, HM15136 may be a novel option for the management of obesity and related metabolic disorders. Human study is ongoing for the clinical relevance of these findings. Disclosure J. Lee: Employee; Self; Hanmi Pharmaceutical. S. Lee: Employee; Self; Hanmi Pharmaceutical. J. Choi: Employee; Self; Hanmi Pharmaceutical. E. Park: Employee; Self; Hanmi Pharmaceutical. J. Lee: Employee; Self; Hanmi Pharmaceutical. S. Lee: Employee; Spouse/Partner; Hanmi Pharmaceutical. S. Bae: Employee; Self; Hanmi Pharmaceutical. D. Kim: Board Member; Self; Hanmi Pharmaceutical. I. Choi: Board Member; Self; Hanmi Pharmaceutical.